Core Viewpoint - The financial report of Haoyuan Pharmaceutical reveals a contradiction of "increased revenue and profit but decreased cash flow," indicating a shortfall in the quality of profitability amid scale expansion, raising alarms about the company's operational health [1] Financial Performance - In the first half of 2025, Haoyuan Pharmaceutical reported operating revenue of 1.311 billion yuan, a year-on-year increase of 24.20%, and a net profit attributable to shareholders of 155 million yuan, a significant year-on-year surge of 115.55% [1] - However, the operating cash flow turned negative, reaching -10.43 million yuan, a sharp decline of 113% year-on-year [1][2] - The company’s inventory impairment provision stood at 332 million yuan, accounting for 20.24% of the inventory book balance [1][3] Cash Flow and Inventory Issues - The negative cash flow is primarily attributed to high accounts receivable and inventory levels, with accounts receivable reaching 610 million yuan, up 16.89% year-on-year, and over 18.7% of accounts receivable being over one year old [2] - Inventory increased to 1.309 billion yuan, a 12.54% year-on-year rise, with over 80% consisting of raw materials and finished goods [2] - The inventory turnover days extended from 186 days in 2022 to 243 days in the first half of 2025, significantly higher than peers such as WuXi AppTec and Kanglong Chemical [2] Business Structure and Profitability - The company’s business is divided into front-end life science reagents and back-end raw materials and intermediates, with the front-end segment achieving revenue of 904 million yuan, a 29.2% increase, and a gross margin of 63.0%, contributing 69.4% of total revenue [5] - The back-end segment generated revenue of 399 million yuan, a 13.6% increase, but its gross margin fell to 17.8%, down from 20.05% in 2024, indicating competitive weaknesses [5] Sales and Marketing Expenses - Sales expenses surged to 130 million yuan, a 33.56% increase year-on-year, with the sales expense ratio rising from 9.25% in 2024 to 9.9% [7] Strategic Challenges - The company faces strategic challenges due to a lack of clear direction following a board reshuffle, with the new leadership failing to establish a coherent strategy for either maintaining traditional markets or advancing into high-end sectors [11][12] - The ongoing price competition from centralized procurement and the inability to secure significant orders due to underutilized capacity further complicate the company's operational landscape [11][12] R&D and Innovation - Haoyuan Pharmaceutical's R&D expenditure was 117 million yuan in the first half of 2025, a 4.23% increase, but the R&D expense ratio decreased from 9.0% in 2024 to 8.9%, falling below industry peers [12] - The company is at risk of being outpaced by technological advancements in the industry, particularly in areas like recombinant technology and synthetic biology, which could threaten its existing business model [13]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In 2024, the company achieved a revenue of 15.839 billion yuan, representing a year-on-year increase of 40.6%. The net profit attributable to the parent company was 3.33 billion yuan, up 63.1% year-on-year, while the net profit excluding non-recurring items was 3.26 billion yuan, an increase of 74.5% year-on-year [2][5]. - The "Twin Stars" product strategy, featuring East Peng Special Drink and Water, has shown significant growth, with revenues of 13.304 billion yuan and 1.495 billion yuan respectively, marking increases of 28.5% and 280.4% year-on-year [11]. - The company is expanding its overseas business, particularly in Southeast Asia and the Middle East, which are seen as key growth areas for future development [11]. Financial Performance - The company reported a Q4 revenue of 3.28 billion yuan, a year-on-year increase of 25.1%, with a net profit of 620 million yuan, up 61.2% year-on-year [2][5]. - The gross margin for the company reached 44.8%, an increase of 1.8 percentage points year-on-year, driven by improved cost efficiency and product demand [11]. - The company expects EPS for 2025, 2026, and 2027 to be 8.71 yuan, 11.20 yuan, and 13.93 yuan respectively, with corresponding PE ratios of 26X, 20X, and 16X [11]. Market Position and Strategy - The company has established nearly 4 million distribution points and over 30,000 refrigerators, with more than 3,000 distributors, indicating a robust channel resource network [11]. - The company’s sales and management expense ratios have decreased, contributing to an improved net profit margin of 21%, up 2.9 percentage points year-on-year [11]. - The company is focusing on a multi-category strategy, enhancing its product portfolio beyond energy drinks, which has led to a more balanced revenue growth across different beverage categories [11].

公司研究丨点评报告丨东鹏饮料（605499.SH） [Table_Title] 东鹏饮料 2024 年年报点评："双子星"产品力 突出，海外业务有序推进 报告要点 [Table_Summary] 2024 年公司实现收入 158.39 亿元，同比+40.6%，归母净利润为 33.3 亿元，同比+63.1%，扣 非归母净利润为 32.6 亿元，同比+74.5%。其中 Q4 收入 32.8 亿元，同比+25.1%，归母净利 润 6.2 亿元，同比+61.2%，扣非归母净利润 6 亿元，同比+62.97%。 分析师及联系人 [Table_Author] 丨证券研究报告丨 董思远 徐爽 冯萱 SAC：S0490517070016 SAC：S0490520030001 SAC：S0490524060001 SFC：BQK487 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 东鹏饮料（605499.SH） cjzqdt11111 [Table_Title 东鹏饮料 2024 2] 年年报点评："双子星"产品力 突出，海外业务有序推进 [Table_Summary2] 事件 ...